Basic Immunology. Lecture 26 th. Immunity against tumors

Similar documents
A listing of human tumor antigens recognized by T cells: March 2004

Four main classes of human tumor antigens recognized by T cells: 1- "Cancer-testis" antigens: non-mutated genes reactivated in neoplastic cells, but

Tumors arise from accumulated genetic mutations. Tumor Immunology (Cancer)

Tumor Immunology. Wirsma Arif Harahap Surgical Oncology Consultant

Bihong Zhao, M.D, Ph.D Department of Pathology

COURSE: Medical Microbiology, PAMB 650/720 - Fall 2008 Lecture 16

Cancer Immunotherapy: Active Immunization Approaches

Immunology CANCER IMMUNOLOGY

5% of patients with genetic immunodeficiency develop a cancer during their lifetime (200x)

MPL W515L K mutation

Spontaneous. Tumour induction. Immunosuppression

Tumor responses (patients responding/ patients treated)

Immune surveillance hypothesis (Macfarlane Burnet, 1950s)

Trial no. Status Phase Treatment Pre-conditioning Primary endpoints Secondary endpoints Diagnosis Sponsor

CURRENT AND EMERGING CANCER DIAGNOSTIC TESTS Emerging Assays, and Companies Developing New Technologies and Products.

LAMPvax DNA Vaccines as Immunotherapy for Cancer - Three Case Studies

CANCER IMMUNOPATHOLOGY. Eryati Darwin Faculty of Medicine Andalas University

TUMOR M ARKERS MARKERS

Vaccins anti-cancer. Claude Leclerc. 7 novembre 2011

Molecular Hematopathology Leukemias I. January 14, 2005

Determination Differentiation. determinated precursor specialized cell

The next steps for effective cancer immunotherapy and viral vaccines. Peter Selby FACP(UK)

Basic Immunology. Lecture 5 th and 6 th Recognition by MHC. Antigen presentation and MHC restriction

JAK2 V617F analysis. Indication: monitoring of therapy

Interaction between the immune system and tumor

Tumor Immunology. Tumor (latin) = swelling

MHC class I MHC class II Structure of MHC antigens:

Structure and Function of Antigen Recognition Molecules

PEPTIDES AS TUMOR ANTIGENS

Cancer Vaccines and Cytokines. Elizabeth A. Mittendorf, MD, PhD Assistant Professor Department of Surgical Oncology

IMMUNOTHERAPY FOR CANCER A NEW HORIZON. Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust

Chapter 4 Cellular Oncogenes ~ 4.6 -

Immunotherapy on the Horizon: Adoptive Cell Therapy

Cross-presentation. Tumor Immunology. The Good News/Bad News Story. Tumor Immunity (Clynes)

Darwinian selection and Newtonian physics wrapped up in systems biology

MCB 4211 Basic Immunology 2nd Exam; 10/26/17 Peoplesoft #:

Tumor Markers & Cytopathology

Cell Biology from an Immune Perspective

Neoplasia 2018 lecture 11. Dr H Awad FRCPath

Tumor immunology. Tried to make things a simple as they can get,,, hope that u enjoy it! ال تخافوا بس أربع صفحات وشوي

CYTOKINE RECEPTORS AND SIGNAL TRANSDUCTION

Cancer Immunotherapy INTRODUCTION HUMAN TUMOR ANTIGENS. Cancer/Germ-Line Antigens

Allergy and Immunology Review Corner: Chapter 19 of Immunology IV: Clinical Applications in Health and Disease, by Joseph A. Bellanti, MD.

Structure and Function of Fusion Gene Products in. Childhood Acute Leukemia

Concepts of cancer immunotherapy

Bases for Immunotherapy in Multiple Myeloma

CHAPTER 18: Immune System

Immunology Lecture 4. Clinical Relevance of the Immune System

the HLA complex Hanna Mustaniemi,

Significance of the MHC

Emerging Targets in Immunotherapy

08/02/59. Tumor Immunotherapy. Development of Tumor Vaccines. Types of Tumor Vaccines. Immunotherapy w/ Cytokine Gene-Transfected Tumor Cells

Antigen Recognition by T cells

Major Histocompatibility Complex (MHC) and T Cell Receptors

T-cell activation T cells migrate to secondary lymphoid tissues where they interact with antigen, antigen-presenting cells, and other lymphocytes:

T-cell activation T cells migrate to secondary lymphoid tissues where they interact with antigen, antigen-presenting cells, and other lymphocytes:

Shiv Pillai Ragon Institute, Massachusetts General Hospital Harvard Medical School

Oncogenes. Dr. S Hosseini-Asl

Antigen Presentation and T Lymphocyte Activation. Abul K. Abbas UCSF. FOCiS

HLA and antigen presentation. Department of Immunology Charles University, 2nd Medical School University Hospital Motol

Tumor Immunity (Clynes)

The Major Histocompatibility Complex (MHC)

Basis and Clinical Applications of Interferon

ACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS. Choompone Sakonwasun, MD (Hons), FRCPT

Haematologica 2000; 85: trends in hematology

Endogenous and Exogenous Vaccination in the Context of Immunologic Checkpoint Blockade

Cover Page. The handle holds various files of this Leiden University dissertation.

UNIVERSITY OF NAIROBI

Rationale for Patient- Specific Vaccine Therapy for Non-Hodgkin Lymphoma

Medical Virology Immunology. Dr. Sameer Naji, MB, BCh, PhD (UK) Head of Basic Medical Sciences Dept. Faculty of Medicine The Hashemite University

Chapter 35 Active Reading Guide The Immune System

Therapeutic Vaccines in Cancer

Immunotherapy of Cancer

Significance of the MHC

Tumor Immunity (Clynes)

Immunology and immunotherapy of human cancer: present concepts and clinical developments

The Panel Approach to Diagnostics. Lauren Hopson International Product Specialist Cell Marque Corporation

TARGETED THERAPY FOR CHILDHOOD CANCERS

Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment

HLA and antigen presentation. Department of Immunology Charles University, 2nd Medical School University Hospital Motol

ACE ImmunoID Biomarker Discovery Solutions ACE ImmunoID Platform for Tumor Immunogenomics

Immune system and cancer. Dr. Zafar A Shah Prof. & Head Department of Immunology and Molecular Medicine SKIMS

Human tumor antigens recognized by T lymphocytes: implications for cancer therapy

Cancer. The fundamental defect is. unregulated cell division. Properties of Cancerous Cells. Causes of Cancer. Altered growth and proliferation

Nucleic Acid Testing - Oncology. Molecular Diagnosis. Gain/Loss of Nucleic Acid. Objectives. MYCN and Neuroblastoma. Molecular Diagnosis

Molecular Diagnosis. Nucleic acid based testing in Oncology

Third line of Defense. Topic 8 Specific Immunity (adaptive) (18) 3 rd Line = Prophylaxis via Immunization!

Respuesta inmune anti-tumoral. Aura Muntasell Institut Hospital del Mar d Investigacions Mèdiques Parc de Recerca Biomèdica de Barcelona

Chapter 1. Chapter 1 Concepts. MCMP422 Immunology and Biologics Immunology is important personally and professionally!

Supplementary Appendix

Phase of immune response

LYMPHOCYTES & IMMUNOGLOBULINS. Dr Mere Kende, Lecturer SMHS

Immuno-Oncology Applications

C. Incorrect! MHC class I molecules are not involved in the process of bridging in ADCC.

Adoptive Cell Therapy: Treating Cancer

Adaptive Immunity. Jeffrey K. Actor, Ph.D. MSB 2.214,

Oncogenes and tumour suppressor genes

Tumour Markers. For these reasons, only a handful of tumour markers are commonly used by most doctors.

Transcription:

Basic Immunology Lecture 26 th Immunity against tumors

Neoplastic transformations are genetic alterations. Expression of cell surface antigens both self and non-self - seen by immune system. Ehrlich positive mechanism eliminating transformed cells. L.Thomas, McFarlane immune surveillance - recognition and destruction of non-self tumor cells on their appearance. Tumor occurrence: immune surveillance is imperfect.

Tumor antigens tumor specific antigens (TSA) (no general tumor specific antigen exists) tumor specific transplantation antigens (TSTA) (mutated self antigens expressed on MHC-I) tumor associated antigens (TAA) (AFP, CEA, hcgβ, PSA, CA, LDH, β2 microglobulin) tumor associated transplantation antigens (TATA) (tumor associated antigens expressed on MHC-I)

AFP Alpha (a)-fetoprotein AIM-2 Interferon-inducible protein absent in melanoma 2 ALL Acute lymphoblastic leukemia AML Acute myeloid leukemia 707-AP 707 alanine proline APL Acute promyelocytic leukemia ART-4 Adenocarcinoma antigen recognized byt cells 4 BAGE B antigen bcr-abl Breakpoint cluster region- Abelson CAMEL CTL-recognized antigen on melanoma CAP-1 Carcinoembryonic antigen peptide-1 CASP-8 Caspase 8 CDC27 Cell division cycle 27 CDK4 Cyclin-dependent kinase 4 CEA Carcinoembryonic antigen CLCA2 Calcium-activated chloride channel 2 CML Chronic myelogenous leukemia CT Cancer-testis (antigen) CTL Cytotoxic T lymphocytes Cyp-B Cyclophilin B DAM Differentiation antigen melanoma (the epitopes of DAM-6 and DAM-10 are equivalent, but the gene sequences are different. DAM-6 is also called MAGE- B2 and DAM-10 is also called MAGE-B1) ELF2 Elongation factor 2 Ep-CAM Epithelial cell adhesion molecule EphA2, 3 Ephrin type-a receptor 2,3 Ets E-26 transforming specific (family of transcription factors) ETV6-AML1 Ets variant gene 6 / acute myeloid leukemia 1 gene ETS FGF-5 Fibroblast growth factor 5 FN Fibronectin G250 Glycoprotein 250 GAGE G antigen GnT-V N-Acetyl glucosaminyl transferase Gp100 Glycoprotein 100 kda HAGE Helicase antigen HER-2/neu Human epidermal receptor 2/neurological HLA-A*0201-R170I Arginine (R) to isoleucine (I) exchange at residue 170 of the a-helix of the a2- domain in the HLA-A2 gene H/N Head and neck HSP70-2 M Heat shock protein 70-2 mutated HST-2 Human signet-ring tumor 2 htert Human telomerase reverse transcriptase ice Intestinal carboxyl esterase IL-13Ra2 Interleukin 13 receptor a2 chain KIAA0205 Name of the gene as it appears in databases LAGE L antigen LDLR/FUT Low density lipid receptor / GDP-L-fucose:b-D-galactosidase 2-a-L-fucosyltransferase MAGE Melanoma antigen MART-1/Melan-A Melanoma antigen recognized by T cells-1 / melanoma antigen A MART-2 Melanoma Ag recognized by T cells-2 MC1R Melanocortin 1 receptor M-CSF Macrophage colony-stimulating factor gene MHC Major histocompatibility complex MSI Microsatellite instability MUC1, 2 Mucin 1, 2 MUM-1, -2, -3 Melanoma ubiquitous mutated 1, 2, 3 NA88-A NA cdna clone of patient M88 Neo-PAP Neo-poly(A) polymerase NPM/ALK Nucleophosmin/anaplastic lymphoma kinase fusion protein NSCLC Non small cell lung carcinoma NY-ESO-1 New York esophageous1 OA1 Ocular albinism type 1 protein OGT O-Linked N-acetylglucosamine transferase gene ORF Open reading frame OS-9 Name of the gene as it appears in databases P15 Protein 15 p190 minor bcr-abl Protein of 190-kDa bcr-abl Pml/RARa Promyelocytic leukemia / retinoic acid receptor a PRAME Preferentially expressed antigen of melanoma PSA Prostate-specific antigen PSMA Prostate-specific membrane antigen PTPRK Receptor-type protein-tyrosine phosphatase kappa RAGE Renal antigen RCC Renal cell carcinoma RU1, 2 Renal ubiquitous 1, 2 SAGE Sarcoma antigen SART-1, -2, -3 Squamous antigen rejecting tumor 1, 2, 3 SCC Squamous cell carcinoma SSX-2 Synovial sarcoma, X breakpoint 2 Survivin-2B Intron 2-retaining survivin SYT/SSX Synaptotagmin I /synovial sarcoma, X fusion protein TAA Tumor-associated antigen TEL/AML1 Translocation Etsfamily leukemia/acute myeloid leukemia 1 TGFbRII Transforming growth factor b receptor 2 TPI Triosephosphate isomerase TRAG-3 Taxol resistant associated protein 3 TRG Testin-related gene TRP-1 Tyrosinase-related protein 1, or gp75 TRP-2 Tyrosinase-related protein 2 TRP-2/INT2 TRP-2/intron 2 TRP-2/6b TRP-2/novel exon 6b TSTA Tumor-specific transplantation antigens WT1

Immune reactions against tumor cells T cell mediated (CD8+, CD4+Th1, NK) macrophage mediated immunoglobulin mediated (ADCC) network of cytotoxic cytokines

Tumor escape Over expression or down regulation of MHC-I. over expression of FcR deficiency of cytokine receptors production of different glycoproteins with masking effects

Possible immuno-therapies immunotargeting through the TAAs Immunomodulation Cytokine therapy Tumor vaccines

Recruitment of dendritic cells by DNA vaccine of GM-CSF

Immunotoxin therapy

HER-2/neu

Immunotoxin therapy of hairy cell leukemia with BL22